 |
|
Is immunological recovery clinically relevant at 100 days after allogeneic transplantation?
Jin Park, Sung Hee Lim, Se Hyung Kim, Jina Yun, Chan Kyu Kim, Sang Cheol Lee, Jong Ho Won, Dae Sik Hong, Seong Kyu Park
Korean J Intern Med. 2020;35(4):957-969. Published online 2020 Apr 21 DOI: https://doi.org/10.3904/kjim.2018.414
|
|
Citations to this article as recorded by
 Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis
Pascal Roland Enok Bonong, Monica Zahreddine, Chantal Buteau, Michel Duval, Louise Laporte, Jacques Lacroix, Caroline Alfieri, Helen Trottier
Vaccines.2021; 9(3): 288. CrossRef Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation
Natasia Rodriguez, Jasme Lee, Lisa Flynn, Fiona Murray, Sean M. Devlin, Cristina Soto, Christina Cho, Parastoo Dahi, Sergio Giralt, Miguel-Angel Perales, Craig Sauter, Doris M. Ponce
Transplantation and Cellular Therapy.2021; 27(11): 920.e1. CrossRef The Roles of γδ T Cells in Hematopoietic Stem Cell Transplantation
Wanyi Ye, Xueting Kong, Wenbin Zhang, Zheng Weng, Xiuli Wu
Cell Transplantation.2020; 29: 096368972096698. CrossRef
|